Salivary duct carcinoma （SDC） is an aggressive tumor with high rates of local recurrence and distant metastasis. Therapeutic options for the patient with local recurrence or distant metastasis of SDC are limited. Immunohistochemical studies have demonstrated that androgen receptor expression is high in SDC. We present a case of a 64-year-old man with locally advanced androgen receptor-positive submandibular gland SDC. He underwent submandibular gland resection with modified neck dissection and postoperative concurrent chemoradiation therapy. Local recurrences were observed 6 months later, and multiple bone metastases were found 17 months later. Then, anti-androgen therapy was started with oral bicalutamide （80mg/day）. Radiotherapy of 30Gy/10Fr was added for the treatment of his backache. After 7 months of bicalutamide treatment, MRI findings showed that the bone metastases had decreased obviously. Breast swelling appeared as a possible adverse effect. He continued bicalutamide treatment for more than 12 months.
We consider that anti-androgen therapy is a beneficial therapeutic tool for patients with progressive SDC.